Half-Year 2022 Financial Performance
Delivering CAPEX projects to support long term growth
Expanding offering across modalities.
Bend, US
Small Molecules
• Early clinical phase
development and
manufacturing
facility
Visp, CH
Biologics
Opening of
Kodiak's facility in
Lonza's IbexⓇ
Dedicate Biopark
• Commercial mRNA
capacity
Stein, CH
Biologics
• New large-scale,
commercial drug
product fill and finish
facility
I
I
I
Lonza
Continuous investment in an
ambitious portfolio of projects
to meet the future needs of our
customers
-
Investment across divisions to
expand capabilities
H1 2022 CAPEX reported at
28.2% of Sales
Tampa, US
Small Molecules
•
Expanded
inhalation
capabilities
Puebla, MX
Capsules and Health
Ingredients
New capsule production line.
Further lines in Greenwood
(US), Haryana (IN), Suzhou
(CN), Colmar (FR)
L
CAPEX investments coming online in H1 2022
Nansha, CN
Small Molecules
• Extended cGMP
HPAPI lab
capacities and
capabilities
Investments announced in H1 2022 (part of planned CAPEX)
8View entire presentation